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Introduction {#s1}
============

Several studies in the recent decade have supported a relationship between different types of infections and CHD (Coronary Heart Disease); however, such a relationship is not definitely proven. Bacteria such as *Helicobacter pylori* have been found effective on the development of atherosclerosis ([@R1], [@R2]). Prevalence of *Helicobacter pylori* infection in Iran exceeds 80%; although, this rate has started a declining trend in the recent years ([@R3]). There is a mutual relationship between the infection and hygiene condition in the society, so that prevalence of the infection is high in the developing countries including Iran.([@R4]).

The role of inflammation mechanism in pathogens and progress of CAD (Coronary Artery Disease) has been widely discussed; although, the mechanism is not clearly known yet. It is believed that the chronic inflammation caused by chronic infections (e.g. *Helicobacter pylori*) may result in advanced atherosclerosis and CAD consequently ([@R2]). Raijasekhar et al. showed in their study that high levels of C-reactive protein, lipids, lipoproteins, and coronary risk factors in the patients with unstable angina and positive *Helicobacter pylori* indicated that the pathogen may affect the risk factors of coronary arteries and had a role to play as a pathogen of atherosclerosis. Tamura et al. carried out a study in Japan and reported that *Helicobacter pylori* infection led atrophic gastritis into a chronic disease, which in turn reduced vitamin B12 in the plasma and folic acid level. These changes result in an increase in homocysteine level, which is a risk factor for atherosclerosis ([@R5]-[@R7]).

Several studies have reported a relationship between Helicobacter infection and IHD, while some have rejected such a relationship ([@R8]-[@R11]). Mandell et al. were the first group to examine the relationship between *Helicobacter pylori* infection and development of CHD and they found a significant relationship between the infection and the disease ([@R12]). Danesh and Peto carried out a meta-analysis of 18 epidemiologic studies on 10000 patients and concluded that there was no significant relationship between *Helicobacter pylori* and CHD ([@R13]). Khodaie et al. showed in their study that MI (Myocardial Infarction) was significantly higher in populations with a higher frequency of Helicobacter infection ([@R14]).

Given the above introduction and the diversity of the results about Helicobacter infection and coronary diseases, the necessity of carrying out a study to determine coronary disease prevalence in the population with Helicobacter infection is quite clear. Since there are no studies supporting a definite the relationship between *Helicobacter pylori* infection and CHD in Iran, the present study was conducted to confirm this theory.

Methods {#s2}
=======

Search strategy {#s2-1}
---------------

In the systematic review and meta-analysis, all casecontrol articles on the relationship between Helicobacter pylori and CHD published from 31^st^ June 2000 to 31^st^ June 2016 indexed in Scopus, PubMed, Google Scholar, Science Direct, and Iranian databases including Magiran, Iran Medex, Irandoc, and SID were included. The articles were searched using the following keywords in Farsi and English. We tried to search titles and/or abstracts of articles published in all mentioned databases, simultaneously. Next, the numbers of searched articles were recorded for each database to calculate the total numbers of searched articles.

*"Helicobacter pylori", "H. pylori"* combined with "cardiovascular disease", "coronary heart disease", "coronary artery disease", "myocardial infarction", "ischemic heart disease", "arteriosclerotic heart disease", "CHD", "CVD", or "CAD".

Study selection and eligibility criteria {#s2-2}
----------------------------------------

Two researchers carried out the search independently and the articles relevant to the purpose of this study were selected based on their title and/or abstract of the articles. In case of disagreement between the two researchers, a third expert assessed the quality of the article. The required data was collected based on the full text of the articles. For the selection of the word to search, the population was CHD patients, comparisons are the controls do not have CHD, and the outcome was the presence of *H. pylori* antibodies in two groups.

Inclusion criteria {#s2-3}
------------------

Case-control studies, carried out in Iranian cities or provinces, on OR (Odds Ratio) of coronary disease due to *Helicobacter pylori* infection were the inclusion criteria. In the case of articles available in two languages, the one published in a more creditable journal would be selected. Most of the papers reported IgG and IgA indices to determine *Helicobacter pylori*, while only IgG index was used in this paper as the measure of infection.

Exclusion criteria {#s2-4}
------------------

Ecologic, cohort, and cross-sectional studies and those that did not report OR and CI (95%) or the data to calculate them, and studies reporting unclear data or possible errors were excluded. The author's name or journal's name had no effect on the selection of articles.

Data extraction {#s2-5}
---------------

After final assessment of the quality of the papers, the data was extracted using a self-administrated checklist. Then the data were entered into a data extraction sheet in Excel by one person. The checklist included name and surname of the first author, year of publication, place of the study, age/mean age of the subjects, gender, sample size, number of cases and controls, OR and CI (95%) extracted using IgG in the two groups under study. We included all articles without considering the methods of laboratory testing for *H. pylori* because our aim was to analyse the total ORs for associations regardless of the clinical methods.

Statistical analysis {#s2-6}
--------------------

The extracted data were imported and analyzed in Stata 12. Based on the heterogeneity of the study (Cochran's Q-test, Higgins and Thompson's I^2^), two statistical models of fixed effect and random effect (CI = 95%) random effects and Der Simonian and Laird methods, sensitivity analysis and Meta-regression method were used for data analyses. To assess the publication bias, Begg's and Egger's tests were used. In addition, sensitivity analysis and Meta-regression method were also used.

Results {#s3}
=======

Thirty case-control studies conducted in different regions of Iran (15 provinces) have been published from 2001 to 2015 and examined in this study ([Table 1](#T1){ref-type="table"}). Totally, 6354 participants (3144 cases and 3210 controls) in these studies. Mean and standard deviation age of the case and control groups were 55.82±4.9and 53.58±5.4year respectively ([Table 2](#T2){ref-type="table"}). In addition, 1430 men and 1109 women were in the case group and 1354 men and 1216 women were in the control group ([Table 2](#T2){ref-type="table"}). The lowest OR was reported by Rahimi F equal to 0.479 (95% CI: (0.267, 0.86)) and the highest OR was reported by Eskandarian et al. equal to 21 (95 CI: (4.45, 99.08)).

###### Characteristics of included studies

  ----------------------------- ------ ------------ ------ --------- ------------------------
  AUTHOR                        YEAR   PLACE        CASE   CONTROL   Type of CAD
  F. Rahimi([@R15])             2001   Tehran       100    100       Coronary Heart Disease
  N. Sarrafzadeh([@R16])        2001   Isfahan      52     55        Myocardial Infarction
  B. Rahnema([@R17])            2001   Tabriz       104    100       Myocardial Infarction
  M. AghaJani([@R18])           2002   Tehran       100    90        Coronary Heart Disease
  F. Jalali([@R19])             2003   Babol        97     141       Myocardial Infarction
  R. Eskandarian([@R20])        2004   Semnan       23     23        Cardiac Syndrome X
  M.A. Bahar([@R21])            2004   Tehran       131    130       Coronary Heart Disease
  R. Eskandarian([@R22])        2006   Semnan       40     40        Cardiac Syndrome X
  A. Amrai([@R23])              2006   Tehran       82     82        Coronary Heart Disease
  F. Raygan([@R24])             2006   Kashan       50     50        Myocardial Infarction
  A.H. Faghihi([@R25])          2007   Tehran       131    130       Coronary Heart Disease
  A. Pourya([@R26])             2007   Kermanshah   30     30        Coronary Heart Disease
  H. Bazazi([@R27])             2008   Gorgan       109    85        Coronary Heart Disease
  N. Sarrafzade([@R28])         2008   Isfahan      57     44        Coronary Heart Disease
  S.M. Mohammadzadeh.([@R29])   2009   Urmia        54     168       Cardiac Syndrome X
  Y. Nozari.([@R30])            2009   Tehran       70     60        Coronary Heart Disease
  H. Bazazi([@R31])             2009   Gorgan       70     70        Myocardial Infarction
  S. Davoudi([@R32])            2010   Tehran       69     84        Coronary Heart Disease
  H. Mirzababaei([@R33])        2010   Tehran       288    294       Coronary Heart Disease
  A. Jafarzadeh.([@R34])        2010   Rafsanjan    60     60        Myocardial Infarction
  Z. Khodai.([@R14])            2010   Tehran,      500    500       Myocardial Infarction
  M. H Khademiansari([@R35])    2009   Tabriz       100    89        Coronary Heart Disease
  Z. Azarkar([@R36])            2011   Birjand      73     78        Myocardial Infarction
  Y. Rasmi([@R37])              2012   Urmia        100    100       Cardiac Syndrome X
  M. Rogha([@R38])              2012   Isfahan      62     43        Coronary Heart Disease
  S. Sayyah([@R39])             2012   Qazvin       40     40        Coronary Heart Disease
  N. Fouladi([@R40])            2012   Ardabil      300    300       Coronary Heart Disease
  H. Honarmand([@R41])          2012   Rasht        100    76        Coronary Heart Disease
  J. Vafaeimanesh([@R42])       2014   Qom          62     58        Coronary Heart Disease
  N. Dehghan([@R43])            2015   Qazvin       90     90        Myocardial Infarction
  ----------------------------- ------ ------------ ------ --------- ------------------------

###### Descriptive Statistics

  ---------------- ---- --------- --------- ------ ------- ----------------
  Variables        N    Minimum   Maximum   Sum    Mean    Std. Deviation
  Case             30   23        500       3144   \-      \-
  Control          30   23        500       3210   \-      \-
  Age Case         25   42        65        \-     55.82   4.9
  Age Control      25   41        62.4      \-     53.58   5.41
  Male Case        23   6         260       1430   \-      \-
  Female Case      23   14        240       1109   \-      \-
  Male Control     23   7         250       1354   \-      \-
  Female Control   23   15        250       1216   \-      \-
  ---------------- ---- --------- --------- ------ ------- ----------------

Based on meta-analysis and the random effects model, general estimate of OR of *Helicobacter pylori* and heart diseases in Iran was 2.351 (95 CI: (1.715, 3.221)). These OR were different for three heart diseases in different papers. In general, OR of heart diseases was 2.36, and this figure is mean of three OR values for three diseases of cardiac syndrome X (OR = 8.2), myocardial infarction (OR = 2.6), and Coronary Heart Disease (OR = 1.7); further details are listed in the table below ([Table 3](#T3){ref-type="table"}).

###### Disease and Odds Ratio

  ------------------------ ------ ----------------- ---------- ---------
  Disease                  OR     95% CI            P -value   Weight%
  Myocardial Infarction    2.6    (1.313 , 5.185)   0.001      30.75%
  Coronary Heart Disease   1.7    (1.264 , 2.31)    0.001      58.53%
  Cardiac syndrome X       8.2    (5.003, 13.56)    0.475      10.72%
  Overall                  2.35   (1.7, 3.2)        0.001      100.00%
  ------------------------ ------ ----------------- ---------- ---------

Odd ratios were obtained based on the number of instances in the case and control groups using the random effects and fixed models. Heterogeneity was determined using I^2^ and Cochran's Q; in addition, heterogeneity test was used to evaluate H0 so that all the papers were examined as to the same effect. Heterogeneity effect was obtained using I^2^, which is a measure of inconsistency between the studies and determines if total percentage of changes between the studies is random or due to heterogeneity; a value of I^2^ bigger than 50% indicates heterogeneity among the studies. Here, I^2^ was equal to 85.6%, p\<0.001; therefore, random effects and Der Simonian and Laird methods were used in addition to the sensitivity analysis and Meta regression method.

Combined OR value was 2.35, which indicates that the OR (of exposure) in the case group was 1.35% higher than that of the control group (p= 0.001) ([Table 4](#T4){ref-type="table"}).

###### Pooled results for 30 case-control studies

  --------------------------- ------ -------- ------------------------ ----------- --------
  Study                       Year   OR       \[95% Conf. Interval\]   \% Weight   
  Myocardial infarction                       Lower                    Upper       
  N. Sarrafzadeh (2001)       2001   13.219   5.096                    34.292      3.05
  B. Rahnema (2001)           2001   3.400    1.727                    6.694)      3.54
  F. Jalali (2003)            2003   0.951    0.567                    1.595       3.80
  H. Bazazi (2009)            2009   3.035    1.383                    6.661       3.35
  Z. Khodai (2010)            2010   7.765    5.829                    10.344      4.09
  Z. Azarkar (2011)           2011   1.788    0.891                    3.590       3.51
  H. Honarmand (2012)         2012   2.024    0.956                    4.283       3.41
  N .Dehghan (2015)           2012   2.579    0.944                    7.049       2.96
  F. Raygan (2006)            2006   0.564    0.218                    1.459       3.06
  Sub-total (D+L pooled OR)   \-     2.609    1.313                    5.185       30.75
  Coronary Heart Disease      \-     \-       \-                       \-          \-
  N. Sarrafzade (2008)        2008   0.829    0.219                    3.136       2.41
  A. Jafarzadeh (2010)        2010   4.643    1.880                    11.467      3.14
  F. Rahimi (2001)            2001   0.479    0.267                    0.860       3.69
  M. AghaJani (2002)          2002   0.897    0.478                    1.683       3.62
  M.A .Bahar (2004)           2004   1.663    1.019                    2.712       3.84
  A .Amrai (2006)             2006   0.598    0.280                    1.278       3.40
  A.H .Faghihi (2007)         2007   1.692    1.036                    2.764       3.84
  A. Pourya (2007)            2007   2.750    0.934                    8.100       2.83
  H. Bazazi (2008)            2008   2.126    0.982                    4.600       3.37
  Y. Nozari (2009)            2009   2.316    1.055                    5.085       3.35
  S. Davoudi (2010)           2010   1.034    0.543                    1.971       3.59
  H. Mirzababai (2010)        2010   3.435    2.443                    4.831       4.03
  M. Rogha (2012)             2012   1.582    0.715                    3.500       3.33
  S. Sayyah (2012)            2012   4.889    1.809                    13.211      2.98
  N .Fouladi (2012)           2012   1.917    1.358                    2.708       4.03
  M. Khademiansari            2009   2.173    1.204                    3.924       3.68
  J .Vafaeimanesh (2014)      2014   2.471    1.156                    5.279       3.40
  Sub-total (D+L pooled OR)   \-     1.708    1.264                    2.310       58.53
  Cardiac syndrome X          \-     \-       \-                       \-          \-
  R. Eskandarian (2004)       2004   11.455   2.167                    60.559      1.94
  R. Eskandarian (2006)       2006   21.000   4.451                    99.082      2.09
  S.M. Mohammadzadeh.         2009   5.726    2.701                    12.138      3.41
  Y. Rasmi (2012)             2012   9.036    3.966                    20.584      3.28
  Sub-total (D+L pooled OR)   \-     8.237    5.003                    13.562      10.72
  Overall (D+L pooled OR)     \-     2.351    1.715                    3.221       100.00
  --------------------------- ------ -------- ------------------------ ----------- --------

Significant publication bias among the included studies (all p\> 0.05), (Figs. 3, 4).
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The random effect model was used to decrease the rate of heterogeneity. We also applied the sensitivity analysis to evaluate the reasons of heterogeneity but the sensitivity analysis was not so useful to detect the reason of heterogeneity. Therefore, we used the Meta-regression method. Variables such as coronary heart disease type, sample size and age of patients were included. Using the Meta-regression we evaluated the simultaneous effect of three mentioned variables. Our analysis showed that the rate of variation due to the heterogeneity was decreased up to 53.88%. At the significant level of 0.05, only the sample size was significant while the variables of sample size, disease 3 and age were significant at 0.1 level of significance ([Tables 5](#T5){ref-type="table"}-[9](#T9){ref-type="table"} & Figs. 5, 6).

###### Test(s) of heterogeneity

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------- ---------- --------------- -------------
                                                                                                                                                                    Heterogeneity statistic   Degrees of freedom   P -value   I-squared\*\*   Tau-squared

  myocardial infarction                                                                                                                                             81.56                     8                    0.001      90.2%           0.957

  Coronary Heart Disease                                                                                                                                            61.15                     16                   0.001      73.8%           0.271

  cardiac syndrome X                                                                                                                                                2.50                      3                    0.475      0.0%            0.000

  Overall                                                                                                                                                           201.68                    29                   0.001      85.6%           0.610

  ^\*\*^I-squared: the variation in OR attributable to heterogeneity), Note: between group heterogeneity not calculated; only valid with inverse variance method\                                                                             
  Significance test(s) of OR=1                                                                                                                                                                                                                

  Myocardial infarction                                                                                                                                             z= 2.74                   p = 0.006                                       

  Coronary Heart Disease                                                                                                                                            z= 3.48                   p = 0.000                                       

  cardiac syndrome X                                                                                                                                                z= 8.29                   p = 0.000                                       

  Overall                                                                                                                                                           z= 5.32                   p = 0.000                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------- ---------- --------------- -------------

###### Meta-regression1

  ------------------------------------------------ ------------------------ ----------------- ------- ---------- ------------------------
  Parameters                                       Coefficient              Standard errors   t       P\>\|t\|   \[95% Conf. Interval\]
  Disease 2                                        -0.42                    0.25              -1.66   0.112      \[-0.94, 0.1\]
  Disease 3                                        0.9                      0.43              2.06    0.053      \[-0.01, 1.82\]
  Sample size                                      0.002                    0.001             2.16    0.043      \[0.001, 0.002\]
  Age                                              -0.05                    0.03              -1.77   0.092      \[-0.115, 0.009\]
  Constant                                         3.77                     1.69              2.23    0.037      \[0.24 , 7.29\]
  Meta-regression                                  Number of obs= 25                                             
  REML estimate of between-study variance          Tau^2^ = 0.155                                                
  \% residual variation due to heterogeneity       I-squared_res = 53.88%                                        
  Proportion of between-study variance explained   Adj R-squared = 66.71%                                        
  Joint test for all covariates                    Model F(4,20) = 6.57                                          
  Prob\> F                                         0.0015                                                        
  ------------------------------------------------ ------------------------ ----------------- ------- ---------- ------------------------

###### Meta-regression 2

  ------------------------------------------------ ------------------------ ----------------- ------- ---------- ------------------------
  Parameters                                       Coefficient              Standard errors   t       P\>\|t\|   \[95% Conf. Interval\]
  Constant                                         6.64                     1.82              3.63    0.001      \[2.86 , 10.42\]
  Age                                              -0.10                    0.03              -3.11   0.005      \[-0.17 , -0.03\]
  Meta-regression                                  Number of obs= 25                                             
  REML estimate of between-study variance          Tau^2^ = 0.3415                                               
  \% residual variation due to heterogeneity       I-squared_res = 77.67%                                        
  Proportion of between-study variance explained   Adj R-squared = 26.67%                                        
  ------------------------------------------------ ------------------------ ----------------- ------- ---------- ------------------------

###### Meta-regression 3

  ------------------------------------------------ ------------------------ ----------------- ------ ---------- ------------------------
  Parameters                                       Coefficient              Standard errors   t      P\>\|t\|   \[95% Conf. Interval\]
  Sample size                                      0.001                    \< 0.01           0.93   0.35       \[- 0.001, 0.002\]
  Constant                                         0.68                     0.24              2.76   0.01       \[0.17 , 1.18\]
  Meta-regression                                  Number of obs30                                              
  REML estimate of between-study variance          Tau^2^ = 0.5865                                              
  \% residual variation due to heterogeneity       I-squared_res = 79.99%                                       
  Proportion of between-study variance explained   Adj R-squared = 2.24%                                        
  ------------------------------------------------ ------------------------ ----------------- ------ ---------- ------------------------

###### Meta-regression 4

  ----------------------------------------------------- ------------------------- ----------------- ------- ---------- ------------------------
  Parameters                                            Coefficient               Standard errors   t       P\>\|t\|   \[95% Conf. Interval\]

  Disease1                                              -1.27                     0\. 49            -2.55   0.017      \[-2.3, -0.24\]

  Disease2                                              -1.7                      0.46              -3.63   0.001      \[-2.66, -0.74\]

  Constant                                              2.23                      0.43              5.18    \< 0.001   \[1.35, 3.12\]

  Meta-regression                                       Number of obs30                                                

  REML estimate of between-study variance               Tau^2^ = 0.4102                                                

  \% residual variation due to heterogeneity            I-squared_res = 81.40%                                         

  The proportion of between-study variance explained\   Adj R-squared = 31.63%\                                        
  Joint test for all covariates\                        Model F (2,27) = 6.79\                                         
  Prob\> F                                              = 0.0041                                                       
  ----------------------------------------------------- ------------------------- ----------------- ------- ---------- ------------------------
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The Meta-regression analysis showed that the OR of having *H. pylori* had a negative correlation with the age of participants (p=0.005), ([Table 7](#T7){ref-type="table"}, [Fig. 5](#F5){ref-type="fig"}).

Discussion {#s4}
==========

The results about the relationship between *Helicobacter pylori* infection and heart diseases were inconsistent, and despite several studies in this field, one cannot be sure about such relationship. The present study is the only systematic review study in Iran on this topic.

The findings showed that OR of heart diseases in case groups with *Helicobacter pylori* infection was higher than that of the control group without the infection. Total OR of heart diseases in the case group was 2.35 times higher than that of the control group.

Mendel et al. conducted one of earliest studies on the relationship between *Helicobacter pylori* and OR of heart diseases. They studied 111 patients and 74 healthy participants in case and control groups respectively and compared them in terms of Helicobacter infection and risk of heart diseases. They reported that OR of heart diseases in the presence of the infection was two times more than that without the infection ([@R12]). Their results are consistent with our results. Their study raised the worries about the probable relationship between Helicobacter infection and heart diseases and followed by several studies conducted in this area in the following years. Inconsistent results have been reported by different studies so that some have found a positive relationship and some have reported no significant relationship between the variables ([@R44]). The results of the present review study showed that studies with small sample group reported higher OR of heart diseases in presence of *Helicobacter pylori* infection. On the other hand, studies with large sample group on controlling the main risk factors of heart diseases found no such relationship ([@R45]). To reach a conclusion, all studies conducted in Iran on the relationship between *Helicobacter pylori* and heart diseases were included regardless of their sample size.

A study based on polymerase chain reaction (PCR) to diagnose *Helicobacter pylori* infection coronary arteries plaque in patients under coronary artery bypass grafting (CABG) showed that 29.5% of the surgery patients had positive *Helicobacter pylori* infection culture. Serology evidences of infection were observed in 53.3% of 105 patients. Therefore, *Helicobacter pylori* infection was effective on raptured plaque and development of the coronary ischemic disease. It is believed that chronic inflammation caused by chronic infections may lead to the development of advanced atherosclerosis and CAD consequently ([@R46], [@R47]).

The results showed that OR of MI in people with Helicobacter infection was 2.5 times more than individuals without the infection ([@R48], [@R49]). Results of one of the few studies conducted as a systematic review work at international level to examine the relationship between *Helicobacter pylori* infection and MI indicated that OR of MI in patients with this type of infection was 1.73 times more than those without the infection and after removing the lower quality articles, the OR was increased to 2.1 that was consistent with results of the present study. It is notable, however, that the OR of MI in Asian populations with Helicobacter infection was 1.75 times more than that of the control group. This shows that OR of Helicobacter infection in Iranian population is higher than that of other Asian countries ([@R49]). Consistently, a study in India reported that risk of MI in individuals with Helicobacter infection was 2.5 times more than that of those without the infection ([@R29]). In addition, several other studies have shown a relationship between Helicobacter infection and MI so that the group with the infection had higher OR of MI‏. Prevalence of Helicobacter infection was relatively high in both control and case groups ([@R50]-[@R52]).

Some authors have argued that *Helicobacter pylori* infection increases the risk of cardiovascular diseases. There are several mechanisms to explain how the infection increases the risk of heart diseases. It is believed that chronic inflammation caused by chronic infections may lead to advanced atherosclerosis, which in turn results in CAD. Chronic infection increases inflammatory metabolites such as cytokines, which in turn influences arteries motions, disrupts endothelium functions, and causes excessive contraction of small arteries. Increase in cytokines concentration has been reported in many patients with *Helicobacter pylori* infection. Higher concentration of cytokines increases leukocytes, which in turn increases the risk of inflammatory reaction in the patients with the infection. These inflammatory reactions may explain the correlation between *Helicobacter pylori* infection and heart diseases. Different bacterial and viral infections may have cross-reaction with classic risk factors of heart diseases such as smoking, hypertension, diabetes, lipid disorders, and other pre-inflammatory stimulators (e.g. homocysteine, free radicals, cytokines, and chemokines) so that the outcome would be local and systemic intra-artery inflammation, which in turn results in atherosclerosis and thrombosis([@R22]). Taking into account that the bacteria can prevent blood supply to walls of the heart, *Helicobacter pylori* infection may directly act as a pathogen on the wall of arteries and cause coronary diseases or indirectly cause inflammation([@R53], [@R54]). If the relationship between *Helicobacter pylori* infection and cardiovascular diseases is proven, one may conclude that treating the infection reduces OR of the diseases and the pertinent events.

Conclusion {#s5}
==========

Following a comprehensive research approach, the relationship between *Helicobacter pylori* infection and risk of heart diseases was examined. Thirty articles were surveyed, and the result showed that OR of heart diseases in the subjects with *Helicobacter pylori* was two times more than that in the subjects without the infection. Since most of the hosts of the bacterium are afflicted with the infection in their childhood, personal hygiene promotion and preventive programs for children may have a considerable role in reducing the risk of the infection and cardiovascular diseases consequently.

Limitations {#s6}
===========

Although the results indicated that Helicobacter infection doubles OR of cardiovascular diseases, interpreting the data of the infections is not easy due to some disturbing variables such as childhood poverty and/or other similar factors. Future works need to take the socioeconomic condition of the participants into account in examining the relationship between the infection and cardiovascular diseases
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